10 March 2020 07:00 GMT
�
Transactions by Persons Discharging Managerial Responsibilities
�
AstraZeneca PLC (the Company) announced that, on 6 March 2020, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.
�
| PDMR | Ordinary Shares granted under the AZDBP | Ordinary Shares granted under the AZPSP | Award price per Ordinary Share |
| Pascal Soriot | 8,734 | 87,346 | �73.76 |
| Marc Dunoyer | 4,323 | 41,501 | �73.76 |
�
The AZDBP award represents the portion of each PDMR's annual bonus for 2019 that they are required to defer into shares. The Ordinary Shares granted under the AZDBP are subject to a three-year holding period and are due to vest on the third anniversary of grant.
�
The AZPSP award is subject to a combination of performance measures focused on scientific, commercial and financial performance assessed over a three-year performance period (1 January 2020 to 31 December 2022). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.
�
Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2019, which is available on the Company's website at www.astrazeneca.com/annualreport2019.
�
| 1 � | Details of the person discharging managerial responsibilities / person closely associated � | |||||
| a) � | Name � � | Pascal Soriot | ||||
| 2 � | Reason for the notification � | |||||
| a) � | Position/status � � | Chief Executive Officer | ||||
| b) � | Initial notification /Amendment � � | Initial notification | ||||
| 3 � | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor � | |||||
| a) � | Name � � | AstraZeneca PLC | ||||
| b) � | LEI � � | PY6ZZQWO2IZFZC3IOL08 | ||||
| 4 � | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted � � | |||||
| a) � | Description of the financial instrument, type of instrument � Identification code � � | Ordinary Shares of US$0.25 each in AstraZeneca PLC � � GB0009895292 � | ||||
| b) � | Nature of the transaction � � | Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan | ||||
| c) � | Price(s) and volume(s) � � | �
� � | ||||
| d) � | Aggregated information � � - Aggregated volume � � - Price � � | Not applicable - single transaction � � � | ||||
| e) � | Date of the transaction � � | 6 March 2020 | ||||
| f) � | Place of the transaction � � | Outside a trading venue | ||||
�
| 1 � | Details of the person discharging managerial responsibilities / person closely associated � | |||||
| a) � | Name � � | Marc Dunoyer | ||||
| 2 � | Reason for the notification � | |||||
| a) � | Position/status � � | Chief Financial Officer | ||||
| b) � | Initial notification /Amendment � � | Initial notification | ||||
| 3 � | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor � | |||||
| a) � | Name � � | AstraZeneca PLC | ||||
| b) � | LEI � � | PY6ZZQWO2IZFZC3IOL08 | ||||
| 4 � | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted � � | |||||
| a) � | Description of the financial instrument, type of instrument � Identification code � � | Ordinary Shares of US$0.25 each in AstraZeneca PLC � � GB0009895292 � | ||||
| b) � | Nature of the transaction � � | Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan | ||||
| c) � | Price(s) and volume(s) � � | �
� � | ||||
| d) � | Aggregated information � � - Aggregated volume � � - Price � � | Not applicable - single transaction � � � | ||||
| e) � | Date of the transaction � � | 6 March 2020 | ||||
| f) � | Place of the transaction � � | Outside a trading venue | ||||
�
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
| Media Relations | | |
| Gonzalo Vi�a | | +44 203 749 5916 |
| Rob Skelding | Oncology | +44 203 749 5821 |
| Rebecca Einhorn | Oncology | +1 301 518 4122 |
| Matt Kent | BioPharmaceuticals | +44 203 749 5906 |
| Angela Fiorin | BioPharmaceuticals | +44 1223 344 690 |
| Jennifer Hursit | Other | +44 203�749 5762 |
| Christina Malmberg H�gerstrand | Sweden | +46 8�552 53 106 |
| Michele Meixell | US | +1 302 885 2677 |
| Investor Relations | | |
| Thomas Kudsk Larsen | | +44 203 749 5712 |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Christer Gruvris | BioPharmaceuticals (Cardiovascular, Metabolism) | +44 203 749 5711 |
| Nick Stone | BioPharmaceuticals (Renal) Environmental, Social and Governance | +44 203 749 5716 |
| Josie Afolabi | BioPharmaceuticals (Respiratory) � | +44 203 749 5631 |
| Tom Waldron | Other medicines | +44 7385 033 717 |
| Craig Marks | Finance Fixed income | +44 7881 615 764 |
| Jennifer Kretzmann | Corporate access Retail investors | +44 203 749 5824 |
| US toll-free | | +1 866 381 72 77 |
Adrian Kemp
Company Secretary
AstraZeneca PLC